Junji Kishimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junji Kishimoto has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Koji Todaka
Center for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan
3 shared publications Hiroyuki Tsutsui
Kyushu University, Japan
2 shared publications- Hiroyuki Tsutsui
Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
2 shared publications - Ikuyo Ichi
Institute for Human Life Innovation, Ochanomizu University, Tokyo, Japan; Natural Science Division, Faculty of Core Research, Ochanomizu University, Tokyo, Japan
2 shared publications - Keiji Oi
Department of Cardiovascular Medicine, Harasanshin Hospital, Fukuoka 812-0033, Japan
2 shared publications - Kenichi Eshima
Matsuguchi Internal Medicine and Cardiology Clinic, Fukuoka 814-0133, Japan
2 shared publications
Latest Publications
- Open Access
- 26 June 2026
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 31 (1)
The validity and reliability of the “Factors Related to Theft by Patients with Eating Disorders Questionnaire”
Purpose Although kleptomania is frequently observed in patients with eating disorders, research on its causes is scarce, and no scale exists to assess it. This pilot study was done to develop such a scale and to evaluate its validity and reliability. Methods Forty-six female patients with anorexia nervosa incarcerated at the Kitakyushu Medical Prison completed our newly developed questionnaire that is based on the DSM-5 diagnostic criteria for kleptomania. All participants had developed an eating disorder prior to their initial incarceration in a correctional facility, had no history of stimulant abuse, and were incarcerated for theft. Results Factor analysis (principal axis method, Promax rotation) identified three significant factors: “Elation/Pleasure”, “Material/Monetary Desire”, and “Impulsivity.” The test–retest correlation coefficients for each item were generally high, confirming test–retest reliability. While the Cronbach’s alpha coefficients for items with high factor loadings on each factor were moderate, the correlations between factors were low, suggesting that each factor represents an independent construct. The “Elation/Pleasure” factor aligned with DSM diagnostic criteria B and C, the “Impulsivity” factor aligned with Criterion A, and the “Material/Monetary Desire” factor contradicted Criterion A. Conclusion These preliminary findings suggest the validity and reliability of this questionnaire, which indicates that it may be useful as a foundational resource and contribute to the advancement of this field. Level of evidence III: Retrospective observational study.
- 26 June 2026
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 31 (1)
Open AccessThe validity and reliability of the “Factors Related to Theft by Patients with Eating Disorders Questionnaire”
Purpose Although kleptomania is frequently observed in patients with eating disorders, research on its causes is scarce, and no scale exists to assess it. This pilot study was done to develop such a scale and to evaluate its validity and reliability. Methods Forty-six female patients with anorexia nervosa incarcerated at the Kitakyushu Medical Prison completed our newly developed questionnaire that is based on the DSM-5 diagnostic criteria for kleptomania. All participants had developed an eating disorder prior to their initial incarceration in a correctional facility, had no history of stimulant abuse, and were incarcerated for theft. Results Factor analysis (principal axis method, Promax rotation) identified three significant factors: “Elation/Pleasure”, “Material/Monetary Desire”, and “Impulsivity.” The test–retest correlation coefficients for each item were generally high, confirming test–retest reliability. While the Cronbach’s alpha coefficients for items with high factor loadings on each factor were moderate, the correlations between factors were low, suggesting that each factor represents an independent construct. The “Elation/Pleasure” factor aligned with DSM diagnostic criteria B and C, the “Impulsivity” factor aligned with Criterion A, and the “Material/Monetary Desire” factor contradicted Criterion A. Conclusion These preliminary findings suggest the validity and reliability of this questionnaire, which indicates that it may be useful as a foundational resource and contribute to the advancement of this field. Level of evidence III: Retrospective observational study.
- Open Access
A phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)
Background: The clinical significance of adjuvant chemotherapy after lung metastasectomy for colorectal cancer remains unknown. This phase 2 study evaluated adjuvant chemotherapy with modified 5‐fluorouracil/leucovorin and oxaliplatin (mFOLFOX6) after lung metastasectomy.Methods: Eligibility criteria included colorectal adenocarcinoma, first curative resection of ≤4 lung metastases, and no prior chemotherapy. Treatment consisted of 12 cycles of mFOLFOX6. The primary endpoint was the 5‐year overall survival (OS) rate, with the expectation of 50% (threshold, 35%) and a planned sample size of 100 (90% power; alpha error, 5%).Results: Fifty‐two patients were enrolled between July 2011 and July 2014; patient enrollment was closed prematurely because of slow accrual. Excluding four ineligible patients, the characteristics of the 48 patients in the efficacy analysis set were a median age of 62 years (range, 43–75 years), Eastern Cooperative Oncology Group performance status of 0 in 45 patients, prior resection of extrathoracic metastasis in four patients, and postoperative carcinoembryonic antigen within normal range in 43 patients; the status of lung metastasis was single in 34 patients, unilateral in 40 patients, and metachronous in 41 patients; and a disease‐free interval between primary tumor resection and diagnosis of lung metastasis of <2 years in 33 patients. The 5‐year OS rate was 85.2% (95% confidence interval [CI], 71.4%–92.6%), and the 5‐year disease‐free survival rate was 60.2% (95% CI, 44.9%–72.4%). Forty‐one of the 52 patients (78.8%) in the safety analysis set completed 12 cycles of mFOLFOX6. Grade ≥3 adverse events were neutropenia (50.0%), fatigue (7.7%), peripheral sensory neuropathy (7.7%), and other (<5%).Conclusions: Adjuvant chemotherapy with mFOLFOX6 is feasible, and may be effective after lung metastasectomy for colorectal cancer.
Open AccessA phase 2 study of adjuvant chemotherapy with 5‐fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G)
Background: The clinical significance of adjuvant chemotherapy after lung metastasectomy for colorectal cancer remains unknown. This phase 2 study evaluated adjuvant chemotherapy with modified 5‐fluorouracil/leucovorin and oxaliplatin (mFOLFOX6) after lung metastasectomy.Methods: Eligibility criteria included colorectal adenocarcinoma, first curative resection of ≤4 lung metastases, and no prior chemotherapy. Treatment consisted of 12 cycles of mFOLFOX6. The primary endpoint was the 5‐year overall survival (OS) rate, with the expectation of 50% (threshold, 35%) and a planned sample size of 100 (90% power; alpha error, 5%).Results: Fifty‐two patients were enrolled between July 2011 and July 2014; patient enrollment was closed prematurely because of slow accrual. Excluding four ineligible patients, the characteristics of the 48 patients in the efficacy analysis set were a median age of 62 years (range, 43–75 years), Eastern Cooperative Oncology Group performance status of 0 in 45 patients, prior resection of extrathoracic metastasis in four patients, and postoperative carcinoembryonic antigen within normal range in 43 patients; the status of lung metastasis was single in 34 patients, unilateral in 40 patients, and metachronous in 41 patients; and a disease‐free interval between primary tumor resection and diagnosis of lung metastasis of <2 years in 33 patients. The 5‐year OS rate was 85.2% (95% confidence interval [CI], 71.4%–92.6%), and the 5‐year disease‐free survival rate was 60.2% (95% CI, 44.9%–72.4%). Forty‐one of the 52 patients (78.8%) in the safety analysis set completed 12 cycles of mFOLFOX6. Grade ≥3 adverse events were neutropenia (50.0%), fatigue (7.7%), peripheral sensory neuropathy (7.7%), and other (<5%).Conclusions: Adjuvant chemotherapy with mFOLFOX6 is feasible, and may be effective after lung metastasectomy for colorectal cancer.
- Open Access
Stratum Corneum Interleukin‐2 in Facial Eczema at 1‐Month‐Old Predicts Later Atopic Dermatitis
- Open Access
Association of Electrocardiographic Left Ventricular Hypertrophy with Future Renal Function Decline in the General Population
Background: Electrocardiographic left ventricular hypertrophy (LVH) could predict adverse renal outcome in patients with hypertension. This study aimed to investigate the association between electrocardiographic LVH and future decline of renal function in the general population. Methods: This retrospective cohort study included individuals who received population-based health checkups from 2010 to 2019 in Japan. Electrocardiographic LVH was defined according to the Minnesota code. Renal function decline was defined as a decrease of ≥25% in the estimated glomerular filtration rate from baseline to 2 . Multivariate adjusted Cox regression analysis was employed to evaluate the association between electrocardiographic LVH at baseline and renal function decline. Results: Of the 19,825 study participants, 1,263 exhibited electrocardiographic LVH at the baseline visit. The mean follow-up period was 3.4 ± 1.9 years. The incidence rates of renal function decline were 0.30 and 0.78 per 100 person-years in the non-LVH group and LVH groups, respectively. Electrocardiographic LVH was associated with the risk for renal function decline in both unadjusted analysis (hazard ratio 2.50, 95% confidence interval 1.73–3.60, P < 0.001) and adjusted analysis (hazard ratio 1.69, 95% confidence interval 1.14–2.50, P = 0.009). This association was comparable across subgroups stratified by age, sex, body mass index, diagnosed hypertension, systolic blood pressure, hemoglobin A1c, and urinary protein. Conclusions: In the general population, electrocardiographic LVH was associated with future renal function decline. To detect high-risk individuals for renal function decline, electrocardiographic LVH may be useful in the setting of health checkups in the general population. Clinical Perspectives: What is new?: This longitudinal study using a population-based annual health checkup data revealed that electrocardiographic LVH was associated with future renal function decline in the general population. The association between electrocardiographic LVH and future renal function decline was consistent regardless of individual characteristics. What are the clinical implications?: Renal dysfunction is a risk factor for cardiovascular disease and death as well as renal failure. This study shows the prognostic value of electrocardiographic LVH to predict future renal dysfunction in the general population under annual health checkups. Individuals with electrocardiographic LVH may require careful follow-up to prevent and detect the progression of renal dysfunction even if they do not have hypertension.
Open AccessAssociation of Electrocardiographic Left Ventricular Hypertrophy with Future Renal Function Decline in the General Population
Background: Electrocardiographic left ventricular hypertrophy (LVH) could predict adverse renal outcome in patients with hypertension. This study aimed to investigate the association between electrocardiographic LVH and future decline of renal function in the general population. Methods: This retrospective cohort study included individuals who received population-based health checkups from 2010 to 2019 in Japan. Electrocardiographic LVH was defined according to the Minnesota code. Renal function decline was defined as a decrease of ≥25% in the estimated glomerular filtration rate from baseline to 2 . Multivariate adjusted Cox regression analysis was employed to evaluate the association between electrocardiographic LVH at baseline and renal function decline. Results: Of the 19,825 study participants, 1,263 exhibited electrocardiographic LVH at the baseline visit. The mean follow-up period was 3.4 ± 1.9 years. The incidence rates of renal function decline were 0.30 and 0.78 per 100 person-years in the non-LVH group and LVH groups, respectively. Electrocardiographic LVH was associated with the risk for renal function decline in both unadjusted analysis (hazard ratio 2.50, 95% confidence interval 1.73–3.60, P < 0.001) and adjusted analysis (hazard ratio 1.69, 95% confidence interval 1.14–2.50, P = 0.009). This association was comparable across subgroups stratified by age, sex, body mass index, diagnosed hypertension, systolic blood pressure, hemoglobin A1c, and urinary protein. Conclusions: In the general population, electrocardiographic LVH was associated with future renal function decline. To detect high-risk individuals for renal function decline, electrocardiographic LVH may be useful in the setting of health checkups in the general population. Clinical Perspectives: What is new?: This longitudinal study using a population-based annual health checkup data revealed that electrocardiographic LVH was associated with future renal function decline in the general population. The association between electrocardiographic LVH and future renal function decline was consistent regardless of individual characteristics. What are the clinical implications?: Renal dysfunction is a risk factor for cardiovascular disease and death as well as renal failure. This study shows the prognostic value of electrocardiographic LVH to predict future renal dysfunction in the general population under annual health checkups. Individuals with electrocardiographic LVH may require careful follow-up to prevent and detect the progression of renal dysfunction even if they do not have hypertension.
- Open Access
Association of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis
Oxysterols have been implicated in the pathogenesis of cardiovascular diseases. Serum levels of oxysterols could be positively correlated with cholesterol absorption and synthesis. However, physiological regulation of various serum oxysterols is largely unknown. The aim of this study was to investigate the relationship between clinical factors and cholesterol metabolism markers, and identify oxysterols associated with cholesterol absorption and synthesis in patients with coronary artery disease. Subjects (n = 207) who underwent coronary stenting between 2011 and 2013 were studied cross-sectionally. We measured lipid profiles including serum oxysterols. As for the serum biomarkers of cholesterol synthesis and absorption, oxysterol levels were positively correlated with campesterol and lathosterol. Covariance structure analysis revealed that dyslipidemia and statin usage had a positive correlation with “cholesterol absorption”. Statin usage also had a positive correlation with “cholesterol synthesis”. Several oxysterols associated with cholesterol absorption and/or synthesis. In conclusion, we elucidated the potential clinical factors that may affect cholesterol metabolism, and the associations between various oxysterols with cholesterol absorption and/or synthesis in patients with coronary artery disease.
Open AccessAssociation of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis
Oxysterols have been implicated in the pathogenesis of cardiovascular diseases. Serum levels of oxysterols could be positively correlated with cholesterol absorption and synthesis. However, physiological regulation of various serum oxysterols is largely unknown. The aim of this study was to investigate the relationship between clinical factors and cholesterol metabolism markers, and identify oxysterols associated with cholesterol absorption and synthesis in patients with coronary artery disease. Subjects (n = 207) who underwent coronary stenting between 2011 and 2013 were studied cross-sectionally. We measured lipid profiles including serum oxysterols. As for the serum biomarkers of cholesterol synthesis and absorption, oxysterol levels were positively correlated with campesterol and lathosterol. Covariance structure analysis revealed that dyslipidemia and statin usage had a positive correlation with “cholesterol absorption”. Statin usage also had a positive correlation with “cholesterol synthesis”. Several oxysterols associated with cholesterol absorption and/or synthesis. In conclusion, we elucidated the potential clinical factors that may affect cholesterol metabolism, and the associations between various oxysterols with cholesterol absorption and/or synthesis in patients with coronary artery disease.
- Open Access
- 1 June 2023
- Published by MDPI AG in Preprints.org
Association of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis
Oxysterols have been implicated in the pathogenesis of cardiovascular diseases. Serum levels of oxysterols could be positively correlated with cholesterol absorption and synthesis. However, physiological regulation of various serum oxysterols is largely unknown. The aim of this study was to investigate the relationship between clinical factors and cholesterol metabolism markers, and identify oxysterols associated with cholesterol absorption and synthesis in patients with coronary artery disease. Subjects (n=207) who underwent coronary stenting between 2011 and 2013 were studied cross-sectionally. We measured lipid profiles including serum oxysterols. As for the serum biomarkers of cholesterol synthesis and absorption, oxysterol levels were positively correlated with campesterol and lathosterol. Covariance structure analysis revealed that dyslipidemia and statin usage had a positive correlation with “cholesterol absorption”. Statin usage also had a positive correlation with “cholesterol synthesis” Several oxysterols associated with cholesterol absorption and/or synthesis. In conclusion, we elucidated the potential clinical factors that may affect cholesterol metabolism, and the associations between various oxysterols with cholesterol absorption and/or synthesis in patients with coronary artery disease.
- 1 June 2023
- Published by MDPI AG in Preprints.org
Open AccessAssociation of Serum Oxysterols with Cholesterol Metabolism Markers and Clinical Factors in Patients with Coronary Artery Disease: A Covariance Structure Analysis
Oxysterols have been implicated in the pathogenesis of cardiovascular diseases. Serum levels of oxysterols could be positively correlated with cholesterol absorption and synthesis. However, physiological regulation of various serum oxysterols is largely unknown. The aim of this study was to investigate the relationship between clinical factors and cholesterol metabolism markers, and identify oxysterols associated with cholesterol absorption and synthesis in patients with coronary artery disease. Subjects (n=207) who underwent coronary stenting between 2011 and 2013 were studied cross-sectionally. We measured lipid profiles including serum oxysterols. As for the serum biomarkers of cholesterol synthesis and absorption, oxysterol levels were positively correlated with campesterol and lathosterol. Covariance structure analysis revealed that dyslipidemia and statin usage had a positive correlation with “cholesterol absorption”. Statin usage also had a positive correlation with “cholesterol synthesis” Several oxysterols associated with cholesterol absorption and/or synthesis. In conclusion, we elucidated the potential clinical factors that may affect cholesterol metabolism, and the associations between various oxysterols with cholesterol absorption and/or synthesis in patients with coronary artery disease.
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (2) , 110-112
Deep Learning of ECG for the Prediction of Postoperative Atrial Fibrillation
- 1 February 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (2) , 110-112
Deep Learning of ECG for the Prediction of Postoperative Atrial Fibrillation
- Open Access
- 1 November 2022
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 11 (11) , 2208-2215
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
Original Article Association of thyroid transcription factor–1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer Ritsu Ibusuki, Yasuto Yoneshima, Mikiko Hashisako, Norikazu Matsuo, Taishi Harada, Yuko Tsuchiya-Kawano, Junji Kishimoto, Keiichi Ota, Yoshimasa Shiraishi, Eiji Iwama, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto
- 1 November 2022
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 11 (11) , 2208-2215
Open AccessAssociation of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer
Original Article Association of thyroid transcription factor–1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer Ritsu Ibusuki, Yasuto Yoneshima, Mikiko Hashisako, Norikazu Matsuo, Taishi Harada, Yuko Tsuchiya-Kawano, Junji Kishimoto, Keiichi Ota, Yoshimasa Shiraishi, Eiji Iwama, Kentaro Tanaka, Yoshinao Oda, Isamu Okamoto
- 14 September 2022
- Published by Wiley in International Journal of Urology
- Vol. 29 (12) , 1543-1550
A predictive score for detecting vesicoureteral reflux in children with their first Escherichia coli‐induced urinary tract infection
In children with a first Escherichia coli-induced febrile urinary tract infection (fUTI), routine voiding cytourethrography (VCUG) is not recommended for detecting vesicoureteral reflux (VUR). Meanwhile, the sensitivity of renal and bladder ultrasound (RBUS) for detecting VUR is insufficient. Aiming to implement VCUG properly for children with a first E. coli-induced fUTI, we attempted to construct a predictive scoring system for the early screening of VUR. This study enrolled patients aged <2 years of age hospitalized for their first E. coli-induced fUTI during the period when VCUG was implemented for all patients (2007-14, non-selective group [n = 111]) and only for those with VUR-suspected RBUS findings, bacteremia or acute focal bacterial nephritis (2016-19, selective group [n = 102]). We evaluated the accuracy of the current criteria and the VUR predictive score constructed using data from the non-selective group. In the non-selective group, 32 patients had VUR (29%). In the selective group, 20 of 45 VCUG-tested patients had VUR (44%). Among 57 patients not undergoing VCUG in the selective group, 8 had a recurrence of fUTI, 3 of whom were diagnosed with VUR. In the non-selective group, 9 patients with VUR did not fulfill the current criteria and the VUR predictive score consisting of young age, female sex, prolonged fever, hypoproteinemia, hyponatremia and hyperglycemia, showed higher sensitivity, specificity than the current criteria. The current imaging/bacteriological criteria were ineffective in screening for VUR in patients with their first E. coli-induced fUTI. The VUR predictive score can be an accurate indicator for implementing VCUG.
- 14 September 2022
- Published by Wiley in International Journal of Urology
- Vol. 29 (12) , 1543-1550
A predictive score for detecting vesicoureteral reflux in children with their first Escherichia coli‐induced urinary tract infection
In children with a first Escherichia coli-induced febrile urinary tract infection (fUTI), routine voiding cytourethrography (VCUG) is not recommended for detecting vesicoureteral reflux (VUR). Meanwhile, the sensitivity of renal and bladder ultrasound (RBUS) for detecting VUR is insufficient. Aiming to implement VCUG properly for children with a first E. coli-induced fUTI, we attempted to construct a predictive scoring system for the early screening of VUR. This study enrolled patients aged <2 years of age hospitalized for their first E. coli-induced fUTI during the period when VCUG was implemented for all patients (2007-14, non-selective group [n = 111]) and only for those with VUR-suspected RBUS findings, bacteremia or acute focal bacterial nephritis (2016-19, selective group [n = 102]). We evaluated the accuracy of the current criteria and the VUR predictive score constructed using data from the non-selective group. In the non-selective group, 32 patients had VUR (29%). In the selective group, 20 of 45 VCUG-tested patients had VUR (44%). Among 57 patients not undergoing VCUG in the selective group, 8 had a recurrence of fUTI, 3 of whom were diagnosed with VUR. In the non-selective group, 9 patients with VUR did not fulfill the current criteria and the VUR predictive score consisting of young age, female sex, prolonged fever, hypoproteinemia, hyponatremia and hyperglycemia, showed higher sensitivity, specificity than the current criteria. The current imaging/bacteriological criteria were ineffective in screening for VUR in patients with their first E. coli-induced fUTI. The VUR predictive score can be an accurate indicator for implementing VCUG.
- Open Access
Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan
The causal effects of vaccines on Kawasaki disease (KD) remain elusive. We aimed to examine the association between vaccines administered during infancy and the development of KD in Japan. We conducted a multicenter prospective case-control study using questionnaires and compared the vaccination status of infants (age: 6 weeks to 9 months) who developed KD (KD group; n = 102) and those who did not develop KD (non-KD group; n = 139). Next, we performed a case-crossover study of 98 cases in the KD group and compared the status of vaccinations between the case and control periods. We also compared the incidence of KD in children for each 5-year period before and after the addition of new vaccines (2012–2013) using data from the Nationwide Survey of KD. In the case-control study, the vaccination status of the KD and control groups did not differ to a statistically significant extent. Multivariable analysis of the vaccination status and patient backgrounds showed no significant association between vaccination and KD development. In the case-crossover study, the status of vaccinations during the case and control periods did not differ to a statistically significant extent. In the analysis of data from the Nationwide Survey of KD, the incidence of KD in children of ages subject to frequent vaccination showed no significant increases in the latter five years, 2014–2018. Based on these prospective analyses, we confirmed that vaccination in early infancy did not affect the risk of KD.
Open AccessKawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan
The causal effects of vaccines on Kawasaki disease (KD) remain elusive. We aimed to examine the association between vaccines administered during infancy and the development of KD in Japan. We conducted a multicenter prospective case-control study using questionnaires and compared the vaccination status of infants (age: 6 weeks to 9 months) who developed KD (KD group; n = 102) and those who did not develop KD (non-KD group; n = 139). Next, we performed a case-crossover study of 98 cases in the KD group and compared the status of vaccinations between the case and control periods. We also compared the incidence of KD in children for each 5-year period before and after the addition of new vaccines (2012–2013) using data from the Nationwide Survey of KD. In the case-control study, the vaccination status of the KD and control groups did not differ to a statistically significant extent. Multivariable analysis of the vaccination status and patient backgrounds showed no significant association between vaccination and KD development. In the case-crossover study, the status of vaccinations during the case and control periods did not differ to a statistically significant extent. In the analysis of data from the Nationwide Survey of KD, the incidence of KD in children of ages subject to frequent vaccination showed no significant increases in the latter five years, 2014–2018. Based on these prospective analyses, we confirmed that vaccination in early infancy did not affect the risk of KD.